A Case of Combined Hepatocellular-Cholangiocarcinoma with Favorable Response to Systemic Chemotherapy
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is a rare form of primary liver cancer composed of cells with histopathologic features of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). Because of its low incidence, the information on clinical outcomes of cHCC-CC is very limited and there are no published reports describing non-surgical treatment options for cHCC-CC. We report a case of cHCC-CC exhibiting a favorable response to systemic chemotherapy with doxorubicin and cisplatin. A 62-year-old man who recurred after a right lobectomy for cHCC-CC received sorafenib for palliative systemic therapy, but follow up imaging studies showed disease progression. He received 2nd line chemotherapy with doxorubicin at 60 mg/m2 together with cisplatin at 70 mg/m2. After 2 cycles of chemotherapy, a computed tomography scan of the chest showed markedly decreased size and number of the multiple lung metastases. After completing 8 cycles of 2nd line therapy, we changed the regimen to a fluorouracil (5-FU) mono therapy because of the toxicities associated with doxorubicin and cisplatin. To date, the patient has completed his 15th cycle of 5-FU mono therapy with the disease status remaining stable during 18 months of follow-up.
Abstract
Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is a rare form of primary liver cancer composed of cells with histopathologic features of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). Because of its low incidence, the information on clinical outcomes of cHCC-CC is very limited and there are no published reports describing non-surgical treatment options for cHCC-CC. We report a case of cHCC-CC exhibiting a favorable response to systemic chemotherapy with doxorubicin and cisplatin. A 62-year-old man who recurred after a right lobectomy for cHCC-CC received sorafenib for palliative systemic therapy, but follow up imaging studies showed disease progression. He received 2nd line chemotherapy with doxorubicin at 60 mg/m2 together with cisplatin at 70 mg/m2. After 2 cycles of chemotherapy, a computed tomography scan of the chest showed markedly decreased size and number of the multiple lung metastases. After completing 8 cycles of 2nd line therapy, we changed the regimen to a fluorouracil (5-FU) mono therapy because of the toxicities associated with doxorubicin and cisplatin. To date, the patient has completed his 15th cycle of 5-FU mono therapy with the disease status remaining stable during 18 months of follow-up.
참고문헌 (15)
- Goodman ZD, "Combined hepatocellular- cholangiocarcinoma. A histologic and immunohistochemical study", Cancer, 55, pp.124~135 (1985)
- Allen RA, "Combined liver cell and bile duct carcinoma", Am J Pathol, 25, pp.647~655 (1949)
- Jarnagin WR, "Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors", Cancer, 94, pp.2040~2046 (2002)
- Koh KC, "Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma", Am J Surg, 189, pp.120~125 (2005)
- Hayashi H, "A 42-month disease free survival case of combined hepatocellular-cholangiocarcinoma with lymph node metastases treated with multimodal therapy", Gan To Kagaku Ryoho, 33, pp.1941~1943 (2006)
- Kassahun WT, "Management of combined hepatocellular and cholangiocarcinoma", Int J Clin Pract, 62, pp.1271~1278 (2008)
- Tanaka S, "Potentiality of combined hepatocellular and intrahepatic cholangiocellular carcinoma originating from a hepatic precursor cell: Immunohistochemical evidence", Hepatol Res, 32, pp.52~57 (2005)
- Yano Y, "Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases", Jpn J Clin Oncol, 33, pp.283~287 (2003)
- Taguchi J, "A clinicopathological study on combined hepatocellular and cholangiocarcinoma", J Gastroenterol Hepatol, 11, pp.758~764 (1996)
- Maeda Y, "Combined hepatocellular carcinoma and cholangiocellular carcinoma", Nippon Rinsho, 59, pp.401~405 (2001)
- Shimoda M, "Multi-disciplinary treatment for cholangiocellular carcinoma", World J Gastroenterol, 13, pp.1500~1504 (2007)
- Kim KH, "Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma", Ann Surg Oncol, 16, pp.623~629 (2009)
- Chan AC, "Liver transplantation for combined hepatocellular cholangiocarcinoma", Asian J Surg, 30, pp.143~146 (2007)
- Chantajitr S, "Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population", J Hepatobiliary Pancreat Surg, 13, pp.537~542 (2006)
- Dick EA, "Ablative therapy for liver tumours", Gut, 50, pp.733~739 (2002)